The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Continued zenocutuzumab treatment beyond progression in patients with NRG1+ pancreatic cancer and cholangiocarcinoma: Analysis from the phase 2 eNRGy trial.
 
Alison Schram
Consulting or Advisory Role - Blueprint Medicines; Day One Biopharmaceuticals; Endeavor BioMedicines; Flagship Pioneering; PMV Pharma; Pro-Clin Solutions LLC; Redona Therapeutics; Relay Therapeutics; Repare Therapeutics; Schrodinger; Transcode Therapeutics
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Elevation Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Merus (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - PMV Pharma
 
Olumide Gbolahan
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boston Scientific; Cardinal Health; Curio Science; Incyte; Lantheus Medical Imaging; Merus
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Eisai (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); Jazz Pharmaceuticals (Inst); Merus (Inst); Relay Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Cindy Neuzillet
Honoraria - Amgen; AstraZeneca; Baxter; Bristol-Myers Squibb; Fresenius Kabi; GE Healthcare; Incyte; Jazz Pharmaceuticals; Merck; MSD; Mundipharma; Nestlé Health Science; Novartis; Nutricia; OncoSil; OSE Immunotherapeutics; Pierre Fabre; Roche; Sanofi; SERVIER; Taiho Oncology; Théradial; Viatris
Consulting or Advisory Role - Amgen; AstraZeneca; Baxter; Bristol-Myers Squibb; Fresenius Kabi; GE Healthcare; Incyte; Jazz Pharmaceuticals; Merck; MSD; Mundipharma; Nestlé Health Science; Novartis; Nutricia; OncoSil; OSE Immunotherapeutics; Pierre Fabre; Roche; Sanofi; SERVIER; Taiho Oncology; Théradial; Viatris
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Fresenius Kabi (Inst); Nutricia (Inst); OSE Immunotherapeutics (Inst); Roche (Inst); SERVIER (Inst); Viatris (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Baxter; Bristol-Myers Squibb; Fresenius Kabi; GE Healthcare; Incyte; Jazz Pharmaceuticals; Merck; MSD; Mundipharma; Nestlé Health Science; Novartis; Nutricia; OncoSil; OSE Immunotherapeutics; Pierre Fabre; Roche; Sanofi; SERVIER; Taiho Pharmaceutical; Théradial; Viatris
Other Relationship - Cereus Biosciences; PI for Merus/Partner Therapeutics
 
Dirk Arnold
Research Funding - Merus (Inst)
 
Antoine Hollebecque
Honoraria - Amgen; BMS; Eisai; Incyte; MSD Oncology; Relay Therapeutics; SERVIER
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Relay Therapeutics; Sanofi; Spectrum Pharmaceuticals (Inst); Taiho Oncology; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Pierre Fabre; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Richard Greil
Stock and Other Ownership Interests - Lilly (Inst); Novo Nordisk (Inst)
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Novartis; Roche; Sandoz; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; Merck; MSD; Novartis; Roche; Sanofi; Takeda
Research Funding - Abbvie; Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Sandoz (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen-Cilag; MSD; Novartis; Roche
 
Mohammed Al Hallak
Speakers' Bureau - AstraZeneca; Guardant Health; Ipsen; Pfizer; Seagen; Takeda
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Amgen; Bridgebio Pharma; Ellipses Pharma; iOnctura; Mekanistic Therapeutics; Merus; Monte Rosa Therapeutics; Sardona Therapeutics
Research Funding - 280Bio (Inst); AADi (Inst); Adcentrix (Inst); Alnylam (Inst); Alterome (Inst); Amgen (Inst); AstraZenneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cancer Core Europe (Inst); Debiopharm Group (Inst); Exelixis (Inst); Fog Pharmaceuticals (Inst); Fore Biotherapeutics (Inst); Fusion Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Hotspot Pharma (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Immuneering (Inst); Incyte (Inst); Kelun (Inst); Kinnate Biopharma (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); MapKure (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Scorpion Therapeutics (Inst); Storm Therapeutics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Tyra Biosciences (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Vividion Therapeutics (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - 280-Biotech; American Society of Medical Oncology; Dava Oncology; ESMO; Loxo; National Taiwan University Cancer Center; STOP Cancer
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Guidepoint Pharmacy; Sequenom; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Kim Reiss
Honoraria - Mayo Clinic; MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Carisma Therapeutics; Foundation Medicine; Guardant Health; Merus NV; MOMA Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology; GlaxoSmithKline (Inst); Lilly (Inst); Merus NV (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from invention (I)
Expert Testimony - Elmhurst Hospital; NYU School of Medicine
 
Paul La Porte
Research Funding - Merus (Inst)
 
Tormod Kyrre Guren
Consulting or Advisory Role - Incyte (Inst); Merck (Darmstadt) (Inst); SERVIER (Inst)
Speakers' Bureau - Amgen (Inst); Daiichi Sankio (Inst); Pierre Fabre (Inst)
Research Funding - Merus (Inst)
 
Carolyn Ragsdale
Employment - Partner Therapeutics
 
Fiona Garner
Employment - Partner Therapeutics
 
Alejandro Ricart
Employment - Merus
Consulting or Advisory Role - Merus
 
Shola Adeyemi
Employment - Merus NV
Stock and Other Ownership Interests - Merus NV
 
Christoph Springfeld
Consulting or Advisory Role - Bayer; Eisai; MSD; Revolution Medicines; Roche; SERVIER; Taiho Oncology
Travel, Accommodations, Expenses - Servier